Abstract:The underlying neurobiological basis of major depressive disorder remains elusive due to the severity, complexity, and heterogeneity of the disorder. While the traditional monoaminergic hypothesis has largely fallen short in its ability to provide a complete picture of major depressive disorder, emerging preclinical and clinical findings suggest that dysfunctional glutamatergic neurotransmission may underlie the pathophysiology of both major depressive disorder and bipolar depression. In particular, recent studies showing that a single intravenous infusion of the glutamatergic modulator ketamine elicits fast-acting, robust, and relatively sustained antidepressant, antisuicidal, and antianhedonic effects in individuals with treatment-resistant depression have prompted tremendous interest in understanding the mechanisms responsible for ketamine's clinical efficacy. These results, coupled with new evidence of the mechanistic processes underlying ketamine's effects, have led to inventive ways of investigating, repurposing, and expanding research into novel glutamate-based therapeutic targets with superior antidepressant effects but devoid of dissociative side effects. Ketamine's targets include noncompetitive N-methyl-D-aspartate receptor inhibition, α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid throughput potentiation coupled with downstream signaling changes, and N-methyl-D-aspartate receptor targets localized on gamma-aminobutyric acid-ergic interneurons. Here, we review ketamine and other potentially novel glutamate-based treatments for treatment-resistant depression, including N-methyl-D-aspartate receptor antagonists, glycine binding site ligands, metabotropic glutamate receptor modulators, and other glutamatergic modulators. Both the putative mechanisms of action of these agents and clinically relevant studies are described.

3,4-Dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide analogs act as potential AMPA receptor potentiators with antidepressant activity

A Bright Future of Researching AMPA Receptor Agonists for Depression Treatment

Discovery of Novel and Potent <i>N</i>-Methyl-D-aspartate Receptor Positive Allosteric Modulators with Antidepressant-like Activity in Rodent Models

Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants

Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/H3 Agents: Synthesis and Biological Evaluation

Design, Synthesis and Biological Evaluation of Novel Ketamine Derivatives as NMDAR Antagonists

Antidepressant-Like Effects of CX717, a Positive Allosteric Modulator of AMPA Receptors

Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile

The Involvement of AMPA–ERK1/2–BDNF Pathway in the Mechanism of New Antidepressant Action of Prokinetic Meranzin Hydrate

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Synthesis and biological evaluation of novel isobenzofuran-1(3H)-one derivatives as antidepressant agents

Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors

Scaffold Hopping Toward Agomelatine: Novel 3, 4-Dihydroisoquinoline Compounds as Potential Antidepressant Agents

Uncovering the Underlying Mechanisms of Ketamine As a Novel Antidepressant

Discovery of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists Containing an Isoxazolylpyridine Ether Scaffold That Demonstrate Antidepressant-like Activity. Part II

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Synthesis and evaluation of amide, sulfonamide and urea – benzisoxazole derivatives as potential atypical antipsychotics

Advances in NMDA receptors-related antidepressants

The Potent and Selective Α4β2/α6-Nicotinic Acetylcholine Receptor Partial Agonist 2-[5-[5-((s)azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol Demonstrates Antidepressive-Like Behavior in Animal Models and a Favorable ADME-tox Profile.

Synthesis and evaluation of novel 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives as potential antidepressants.

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments